Asset Details
Do you wish to reserve the book?
Oral Anticoagulation Therapy in Atrial Fibrillation Patients with Intermediate Stroke Risk: A Systematic Review and Meta-Analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Oral Anticoagulation Therapy in Atrial Fibrillation Patients with Intermediate Stroke Risk: A Systematic Review and Meta-Analysis
Do you wish to request the book?
Oral Anticoagulation Therapy in Atrial Fibrillation Patients with Intermediate Stroke Risk: A Systematic Review and Meta-Analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Oral Anticoagulation Therapy in Atrial Fibrillation Patients with Intermediate Stroke Risk: A Systematic Review and Meta-Analysis
2025
Overview
Background
Current guidelines recommend that anticoagulation is reasonable and less robust to prevent stroke among AF patients with an intermediate risk of stroke, suggesting the need for more evidence in this population. Therefore, our current systematic review and meta-analysis aimed to evaluate the effectiveness and safety outcomes of oral anticoagulation (OAC) therapy in AF patients with a single additional stroke risk factor (CHA2DS2-VASc score = 1 in males and 2 in females).
Methods
We performed the literature searches to identify relevant articles by systematically researching the PubMed and Embase databases. In the pooled analysis by the random-effects model, the comparative treatment indicators to present outcomes of OAC therapy compared with no OAC were adjusted hazard ratios (HRs) and 95% confidence intervals (CIs).
Results
A total of 6 studies were finally included. In the pooled analysis by the random-effects model, compared with no OAC therapy, OAC use was associated with increased risks of major bleeding (HR = 1.29, 95%CI: 1.06-1.57) and gastrointestinal bleeding (HR = 1.38, 95%CI: 1.04-1.82). There were no differences in stroke or systemic embolism (SSE) (HR = 0.84, 95%CI: 0.66-1.08), ischemic stroke (HR = 0.79, 95%CI: 0.27-2.33), and intracranial bleeding (HR = 1.17, 95%CI: 0.78-1.76) between the two studied groups
Conclusion
In patients with AF patients at an intermediate risk of stroke, OAC use was not associated with reductions in thromboembolic events, but might increase the bleeding risks compared with no treatment.
Publisher
SAGE Publications,SAGE PUBLICATIONS, INC,SAGE Publishing
Subject
/ Anticoagulants - administration & dosage
/ Anticoagulants - pharmacology
/ Anticoagulants - therapeutic use
/ Anticoagulation Therapy in Special Populations: Challenges and Advances
/ Atrial Fibrillation - complications
/ Atrial Fibrillation - drug therapy
/ Evidence
/ Female
/ Humans
/ Male
/ Stroke
